The Application of Realtime Fluorescence Quantitative PCR for Prenatal Screening of Group B Streptococcal Infections
DOI:
https://doi.org/10.30564/jams.v2i3.669Abstract
Objective: In the prenatal screening, several different methods were used to detect the presence of group B streptococcus (GBS) infection, in this assay, the diagnostic value and clinical signifcance of the application of realtime fluorescent PCR were explored. Methods: A total of 86 women with 35-37 weeks pregnancy were enrolled, vaginal secretion samples were collected. Fluorescence PCR, bacterial culture and gene sequencing were used to detect whether there was GBS infection, and the results obtained were compared and analyzed. Results: 10 subjects were detected to be positive for GBS by fluorescence PCR (the positive rate was 11.6%), however, only 4 cases were positive for GBS by bacterial culture method (the positive rate was 4.7%). There was a statistically signifcant difference in the positive rate between the two methods (P<0.01). Compared with the results of gene sequencing, the detection of GBS infection by fluorescence PCR has an accuracy of 95.2%, and the sensitivity was 90.9% with 100% specificity. Conclusion: The application of realtime fluorescence quantitative PCR for the detection of GBS infection is signifcantly better than the use of bacterial culture method. Compared with the gold standard method (gene sequencing method), its detection effciency, accuracy, sensitivity and specifcity are relatively high. In summary, PCR for prenatal screening of GBS is worthy of promotion in clinical practice.
Keywords:
Streptococcus B; Fluorescence quantitative PCR; Bacterial culture; Gene sequencingReferences
[1] Rosen G H , Randis T M , Desai P V , et al. Group B Streptococcus and the vaginal microbiota[J]. The Journal of Infectious Diseases, 2017.
[2] Gao K, Guan X, Zeng L, et al. An increasing trend of neonatal invasive multidrug-resistant group B streptococcus infections in southern China, 2011-2017[J]. Infection and Drug Resistance, 2018:2561-2569.
[3] Rosa-Fraile M , Spellerberg B . Reliable Detection of Group B Streptococcus in the Laboratory Medicine[J]. Journal of Clinical Microbiology, 2017:JCM.00582-17.
[4] Armistead B, Oler E, Waldorf K M, et al. The Double Life of Group B Streptococcus: Asymptomatic Colonizer and Potent Pathogen[J]. Journal of Molecular Biology, 2019.
[5] Biringer K, K B B, Hasko M, et al. Streptococci group B in perinatology[J]. Ceska gynekologie /Ceska lekarska spolecnost J. Ev. Purkyne, 2010,75(5).
[6] Wang X, Ma L K, Song Y N, et al. Rapid Group B streptococcus screening methods in late pregnancy and the maternal-neonatal outcomes[J]. National Medical Journal of China, 2016, 96(15).
[7] Helali N E, Habibi F, Azria E, et al. Point-of-Care Intrapartum Group B Streptococcus Molecular Screening: Effectiveness and Costs[J]. Obstetrics & Gynecology, 2019, 133(2):276-281.
[8] Ji W, Liu H, Jin Z, et al. Disease burden and antimicrobial resistance of invasive group B streptococcus among infants in China: a protocol for a national prospective observational study[J]. Bmc Infectious Diseases, 2017, 17(1):377.
[9] Wang Y, Du Y, Miao X, et al. Risk factors and drug resistance in early-onset neonatal group B streptococcal disease[J]. Journal of Zhejiang University-science B, 2018, 19(12):973-978.
[10] Guo Y, Deng X, Liang Y, et al. The draft genomes and investigation of serotype distribution, antimicrobial resistance of group B Streptococcus strains isolated from urine in Suzhou, China[J]. Annals of Clinical Microbiology and Antimicrobials, 2018, 17(1).
[11] Guo D, Cao X, Li S, et al. Neonatal colonization of group B Streptococcus in China: Prevalence, antimicrobial resistance, serotypes, and molecular characterization[J]. American Journal of Infection Control,2018, 46(3).
Downloads
Issue
Article Type
License
Copyright and Licensing
The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.
Journal of Advances in Medicine Science publishes accepted manuscripts under Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). Authors who submit their papers for publication by Journal of Advances in Medicine Science agree to have the CC BY-NC 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for non-commercial use. As long as you follow the license terms and original source is properly cited, anyone may copy, redistribute the material in any medium or format, remix, transform, and build upon the material.
License Policy for Reuse of Third-Party Materials
If a manuscript submitted to the journal contains the materials which are held in copyright by a third-party, authors are responsible for obtaining permissions from the copyright holder to reuse or republish any previously published figures, illustrations, charts, tables, photographs, and text excerpts, etc. When submitting a manuscript, official written proof of permission must be provided and clearly stated in the cover letter.
The editorial office of the journal has the right to reject/retract articles that reuse third-party materials without permission.
Journal Policies on Data Sharing
We encourage authors to share articles published in our journal to other data platforms, but only if it is noted that it has been published in this journal.